Close

Search

Subscribe
Browse Tag

Tri-specific

2 Articles
Illustration of Simcere Zaiming’s SIM0660 tri-specific antibody engaging CD3 on a T cell and CD19 and CD79a on a B cell to trigger B-cell killing.

Simcere Zaiming Out-Licenses SIM0660, a Tri-specific T-cell Engager, to Roche in $1.53 Billion Global Deal

By Chris Chen
No Comments on Simcere Zaiming Out-Licenses SIM0660, a Tri-specific T-cell Engager, to Roche in $1.53 Billion Global Deal
5 Min Read

Simcere Zaiming, the oncology-focused subsidiary of China’s Simcere Pharmaceutical Group, has entered into an exclusive global licensing agreement with Roche for SIM0660, a preclinical tri-specific T-cell engager targeting CD79a, CD19 and CD3. The…

Hengrui Advances SHR-8203 Into Phase 1/2 Study in Advanced Solid Tumors, With Filing Hinting at Potential PD-1/VEGF/CTLA-4 Trispecific

By Xiaoxin Du
No Comments on Hengrui Advances SHR-8203 Into Phase 1/2 Study in Advanced Solid Tumors, With Filing Hinting at Potential PD-1/VEGF/CTLA-4 Trispecific
4 Min Read

Chinese pharmaceutical giant Hengrui Pharma has registered a new clinical study of SHR-8203 injection on China’s drug trial registration platform, moving the previously undisclosed biologic into a multicenter Phase 1/2 trial in patients with…